Related Experiment Video
Updated: Jul 19, 2026

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
Published on: July 11, 2013
Follicular rash during therapy with erlotinib (Tarceva)
Sascha Gerdes1, Ulrich Mrowietz
1Clinic for Dermatology, Venerology and Allergology, University Clinic Schleswig-Holstein, Campus Kiel, Kiel, Germany. sgerdes@dermatology.uni-kiel.de
Abstract:
Erlotinib is a small-molecule tyrosine kinase inhibitor of the EGF receptor which has become an important oncological agent, used primarily in treating non-small-cell lung cancer. The most common side effects of this class of EGF receptor antagonists are cutaneous rashes. The severity of the skin rash seems to be correlated to clinical response and should be a motivating factor to continue therapy. We report a case of a patient who developed a follicular rash during therapy with erlotinib.
Related Concept Videos
Skin Cancer
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Acne Infection